Is Wall Street Bullish or Bearish on Aflac Stock?

Core Insights - Aflac Incorporated is a leading provider of supplemental health and life insurance, primarily operating in the U.S. and Japan, with a market cap of $59.5 billion [1] - The company's stock has underperformed compared to the broader market, gaining 9.5% over the past 52 weeks, while the S&P 500 Index increased by 12.2% [1] - Year-to-date, Aflac's stock is up 6.5%, contrasting with a slight decline in the S&P 500 [1] - Aflac has outperformed the SPDR S&P Insurance ETF, which saw a 1.8% increase over the past 52 weeks [2] Financial Performance - In Q4 2025, Aflac reported total revenue of $4.9 billion, a decline of 9.3% year-over-year [4] - Adjusted earnings decreased by 5.4% to $818 million, while adjusted EPS rose slightly to $1.57 [4] - Net investment gains fell by 46.3% year-over-year to $537 million, down from $1 billion [4] - Shareholders' equity increased to $29.5 billion, or $56.85 per share, up from $26.1 billion a year earlier, with a strong annualized return on equity of 19% [4] Analyst Expectations - For the current fiscal year ending in December, analysts project Aflac's EPS to decline by 1.7% year-over-year to $7.36 [5] - The consensus rating among 16 analysts is a "Hold," with two "Strong Buy," one "Moderate Buy," nine "Hold," and four "Strong Sell" ratings [5] Market Outlook - Barclays has lowered its price target for Aflac to $101 from $104, maintaining an "Equal-Weight" rating [6] - The firm expresses cautious optimism regarding life insurers, citing strong capital positions and solid cash flow as positives, while noting challenges such as spread compression and rising technology spending [6]